Substitute for form 1449A/PTO	COMPLETE F KNOWN		
INFORMATION DISC. URE	Application Number	10/520,	
STAGEMENT BY APPLICANT	Filing Date	January 7, 2004	
~ W	First Named Inventor	David B. Olsen, et al.	
(use as inany sheets as necessary)	Group Art Unit		
(use as many sheets as necessary)	Examiner Name		
Sheet of 3	Attorney Docket Number	21194P	

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	No.	U.S. Patent Document Kind		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
/MB/	1	6,777,395		Bhat et al.	08/17/2004
	2	6,812,219		LaColla et al.	11/02/2004
	3	US 2003/0060400		LaColla et al.	03/27/2003
	4	US 2003/0050229		Sommadossi et al.	03/13/2003
	5	US 2004/0097461		Sommadossi et al.	05/20/2004
	6	US 2004/0072788		Bhat et al.	04/15/2004
	7	US 2004/0147464		Roberts et al.	07/29/2004
	8	US 2004/0063658		Roberts et al.	04/01/2004
ĪМВ.	9	US 2004/0259934		Olsen et al.	12/23/2004
		•			
				•	·
		·			

	•		FORE	IGN PATENT	T DOCUMENTS	
Examiner Cite		Foreign Patent Document			Date of Publication of	
Initials*		Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY			
<u>/M</u>	₿∤o	PCT	WO02/057425		Merck & Co., Inc.	07/25/2002
1	11	PCT	WO02/32920		Pharmasset Limited	04/25/2002
	12	PCT	WO03/093290		Genelabs Technologies, Inc.	11/13/2003
	13	PCT	WO02/057287		Merck & Co., Inc.	07/25/2002
	14	PCT	WO01/92282		Novirio Pharmaceuticals Limited	12/06/2001
	15_	PCT	WO01/90121		Novirio Pharmaceuticals Limited	11/29/2001
	16	PCT	WO03/051899		Ribapharm Inc.	06/26/2003
	17	PCT	WO03/062255		Ribapharm Inc.	07/31/2003
	18	PCT	WO03/062256		Ribapharm Inc.	07/31/2003
/MB	19	PCT	WO2004/065398		Ribapharm Inc.	08/05/2004

/Mark Berch/ (04/24/2007) Examiner Signature Date Considered

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form 1DS Form (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449APTO		COMPLETES IF KNOWN	
INFORMATION DIS SURE	Application Number	10/52	
REATEMENT DV ADDI ICANT	Filing Date	January 7, 2005	
S FATEMENT BY APPLICANT	First Named Inventor	David B. Olsen, et al.	
APR 0 8 7005 (Use as pipany sheets as necessary)	Group Art Unit		
(use as many sheets as necessary)	Examiner Name		
Street of 3	Attorney Docket Number	21194P	

	U.S. PATENT DOCUMENTS						
Examiner Initials*	, Cite No.	U.S. Patent Document	Kind Code (known)		Date of Publication of Cited Document MM-DD-YYYY		
			<u> </u>				
					•		
			ŀ		·		
		·					
					1		

			FORE	IGN PATEN	T DOCUMENTS		
Examiner Cite		Foreign Patent Document		Name of Patentee or Applicant	Date of Publication of		
Initials*	No.	Office	Number	Kind Code (if known)	of Cited Document	Cited Document MM-DD-YYYY	
	≵o	PCT	WO2004/028481		Genelabs Technologies, Inc.	04/08/2004	
/ME	1	PCT	WO2004/002999		Idenix (Cayman) Limited	01/08/2004	
/MB/	22	PCT	WO2004/002422		Idenix (Cayman) Limited	01/08/2004	
/MB/	23	PCT	WO2004/046331		Idenix (Cayman) Limited	06/03/2004	
	24	PCT	WO2003/068244		Merck & Co., Inc./ Isis Pharm	08/21/2003	
•	25	PCT	WO2003/103770		Merck & Co., Inc./ Isis Pharm.	12/24/2003	
	26		WO2004/007512		Merck & Co., Inc./ Isis Pharm	01/22/2004	
	27		WO2004/009020		Merck & Co., Inc./ Isis Pharm	01/29/2004	
	28-	PCT	WO2004/072090		Merck & Co., Inc.	08/26/2004	
	29	PCT	WO2004/000858		Merck & Co., Inc./ Isis Pharm	12/31/2003	

/Mark Berch/ (04/24/2007) Examiner Signature Date Considered

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form \* IDS Form\* (IDS Form\* (IDS Folder), Merck & Co., Inc., 09/05/2003)

Approved for use through 7/31/2006. OMB 0651-0031 SUBSTITUTE for PTO/SB/08A (08-03), Information Disclusive Statement by Applicant Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

	COMPLE NE KNOWN
Application Number	10/520
Filing Date	January 7, 2004
First Named Inventor	David B. Olsen, et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	21194P
	Application Number Filing Date First Named Inventor Group Art Unit Examiner Name

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/MB	30	Anne B. Eldrup et al., "Structure-Activity Relationship of Heterobase-Modified 2'-C-Methyl Ribonucleosides as Inhibitors of Hepatitis C Virus RNA Replication", J. Med. Chem., Vol. 47, pp. 5284-5297 (2004)
/MB/	31	Anne B. Eldrup et al., "Structure-Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase", J. Med. Chem., Vol. 47, pp. 2283-2295 (2004)
/MB/	32	David B. Olsen et al., "A 7-Deaza-Adenosine Analog is a Potent and Selective Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic Properties", Antimicrobial Agents and Chemotherapy, Vol. 48, No. 10, pp. 3944-3953 (2004)
/MB/	33	Per Hoffmann et. al., "Recent Patents on Experimental Therapy for Hepatitis C Virus Infection", Expert Opin. Ther. Patents, Vol. 13(11), pp. 1707-1723, (2003)
/MB/	34	Volker Brass et al., "Recent Developments in Target Identification against Hepatitis C Virus", Expert Opin. Ther. Targets, Vol. 8(4), pp. 295-307, (2004)
	35	Murair et al., "A synthesis and an x-ray analysis of 2'-C-,3'-C- and 3'-C-Methylsangivamyeths", Heterocycles, vol. 33, pages 391-484 (1992)
	36	Imori et al, "A Study on conformationally restricted sangivamycins and their inhibitory abilities of protein kinases", Nucleic Acids Symposium Series, vol. 27, pages 109-170 (1993); Chemical Abstracts, vol. 118, Abstract No. 160364 (1993)

Examiner Signature	/Mark Berch/ (04/24/2007)	Date	
Digitature		Considered	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form IDS Form\* (IDS Folder), Merck & Co., Inc., 09/05/2003